Market Closed -
Nasdaq
01:30:00 18/05/2024 am IST
5-day change
1st Jan Change
8.26
USD
-1.43%
-10.80%
+38.13%
Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee
June 30, 2022 at 02:46 am IST
The Board of Sera Prognostics, Inc. appointed Dr. Jane Barlow, M.D., to the nominating and governance committee of the Board, effective immediately.
Transcript : Sera Prognostics, Inc., Q1 2024 Earnings Call, May 08, 2024
09/05
Sera Prognostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
09/05
CI
Sera Prognostics Insider Sold Shares Worth $727,853, According to a Recent SEC Filing
29/03
MT
Sera Prognostics Insider Sold Shares Worth $364,484, According to a Recent SEC Filing
27/03
MT
Transcript : Sera Prognostics, Inc., 2023 Earnings Call, Mar 20, 2024
21/03
Earnings Flash (SERA) SERA PROGNOSTICS Posts Q4 Revenue $41,000
21/03
MT
Sera Prognostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
21/03
CI
Sera Prognostics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
21/03
CI
Sector Update: Health Care Stocks Mixed Late Afternoon
07/12
MT
Top Midday Gainers
07/12
MT
Sector Update: Health Care Stocks Rise in Afternoon Trading
07/12
MT
Sector Update: Health Care
07/12
MT
Sera Prognostics Says Study of Preterm Birth Prevention Strategy Met Primary Endpoint Criteria; Shares Surge
06/12
MT
Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success
06/12
CI
Transcript : Sera Prognostics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
09/11
Earnings Flash (SERA) SERA PROGNOSTICS Posts Q3 Revenue $42,000
09/11
MT
Sera Prognostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
09/11
CI
Citigroup Adjusts Price Target on Sera Prognostics to $2.75 From $3.75, Maintains Neutral Rating
10/23/10
MT
Transcript : Sera Prognostics, Inc., Q2 2023 Earnings Call, Aug 09, 2023
10/23/10
Earnings Flash (SERA) SERA PROGNOSTICS Reports Q2 Revenue $123,000
10/23/10
MT
Sera Prognostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
10/23/10
CI
Sera Prognostics, Inc. Announces the Resignation of Michael R. Foley, M.D., as Chief Medical Officer
31/23/31
CI
Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell Microcap Value Index
23/23/23
CI
Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell Microcap Growth Index
23/23/23
CI
Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell 3000E Growth Index
23/23/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
More about the company
1st Jan change
Capi.
+38.13% 27Cr +11.28% 1.68TCr 0.00% 744Cr -13.80% 283.87Cr -8.66% 280.18Cr -29.92% 177.81Cr -1.33% 117.96Cr -6.29% 107.71Cr +2.15% 85Cr -10.83% 83Cr
Testing Laboratories
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1